Group 1: Market Movements - Several biotech and healthcare companies experienced notable gains in after-hours trading, driven by earnings updates, guidance announcements, and broader investor sentiment [1] - FibroBiologics, Inc. (FBLG) led with a 7.68% increase, closing at $0.41, suggesting speculative interest or technical momentum [1] - Nyxoah SA (NYXH) advanced 3.94% to $5.28 after reporting preliminary results for Q4 and full year 2025, along with revenue guidance for Q1 2026 [2] - Fortress Biotech, Inc. (FBIO) climbed 6.90% to $4.49, continuing a trend of volatility despite no new news [2] - Revvity, Inc. (RVTY) gained 4.92% to close at $109.00, with investors likely reacting to a previous collaboration announcement with Eli Lilly [3] - Option Care Health, Inc. (OPCH) rose 3.28% to $33.11 after releasing preliminary unaudited financial results for Q4 and full year 2025, along with guidance for 2026 [4] - Actinium Pharmaceuticals, Inc. (ATNM) added 3.02% to close at $1.34, reflecting investor activity in the broader biotech sector [4] - Design Therapeutics, Inc. (DSGN) gained 1.97% to $9.30, indicating continued interest despite no specific news [5] Group 2: Company-Specific Developments - FibroBiologics, Inc. (FBLG) showed a significant rise without any company-specific news, indicating potential speculative interest [1] - Nyxoah SA (NYXH) provided revenue guidance for Q1 2026, which bolstered investor confidence in its growth trajectory [2] - Revvity, Inc. (RVTY) is expanding access to predictive models through a collaboration with Eli Lilly, aimed at accelerating AI-enabled drug discovery [3] - Option Care Health, Inc. (OPCH) released preliminary financial results and guidance, contributing to its positive after-hours reaction [4]

Core Insights - Several biotech and therapeutics companies experienced significant gains in after-hours trading on December 2, 2025, driven by corporate updates, investor anticipation, and scientific disclosures [1] Company Updates - Clene Inc. (CLNN) shares surged 8.53% to $10.05 after a regular session close of $9.26, following the announcement of an upcoming update on its CNM-Au8 program for ALS, which is expected to boost investor optimism [2] - Werewolf Therapeutics, Inc. (HOWL) advanced 6.12% to $0.91, recovering from a decline, as investors reacted to the company's presentation at the Society for Immunotherapy of Cancer's Annual Meeting and its narrower Q3 net loss of $16.4 million compared to the previous year [3] - Biomea Fusion, Inc. (BMEA) gained 7.31% to $1.03 after announcing its selection for an oral presentation at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease, showcasing advancements in metabolic disease research [4] - Denali Therapeutics Inc. (DNLI) rose 3.14% to $18.40 despite no new news, indicating steady investor interest in the neurodegenerative disease sector [5] - TScan Therapeutics, Inc. (TCRX) added 3.97% to $0.99, recovering from a drop, with Q3 revenue growth reported at $2.5 million, up from $1.0 million a year earlier, despite widening net losses to $35.7 million [6] - Nyxoah SA (NYXH) climbed 4.03% to $4.90, following an increase in insider voting rights to 10.14%, reflecting growing insider ownership [7] - Dyne Therapeutics, Inc. (DYN) rose 4.80% to $20.95, despite widening net losses to $108.0 million in Q3, compared to $97.1 million a year earlier, as it advances its muscle disease therapy pipeline [8] - Outlook Therapeutics, Inc. (OTLK) gained 3.83% to $1.90, with no new updates but reflecting investor positioning ahead of regulatory milestones for its ophthalmic drug candidate [9]

Core Insights - Nyxoah SA reported a quarterly loss of $0.74 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.61, and compared to a loss of $0.55 per share a year ago, indicating a significant earnings surprise of -21.31% [1] - The company generated revenues of $2.31 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 18.02%, and showing an increase from $1.39 million in the same quarter last year [2] - Nyxoah shares have declined approximately 26.4% year-to-date, contrasting with the S&P 500's gain of 16.5% [3] Financial Performance - Over the last four quarters, Nyxoah has only surpassed consensus EPS estimates once [2] - The current consensus EPS estimate for the upcoming quarter is -$0.58 on revenues of $3.59 million, and for the current fiscal year, it is -$2.52 on revenues of $8.34 million [7] Market Outlook - The estimate revisions trend for Nyxoah was unfavorable prior to the earnings release, resulting in a Zacks Rank 4 (Sell), suggesting expected underperformance in the near future [6] - The outlook for the Medical Info Systems industry, where Nyxoah operates, is currently in the top 30% of over 250 Zacks industries, indicating a favorable environment that could impact stock performance positively [8]

Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for 10x Genomics despite lower revenues, with a focus on how actual results will compare to estimates [1][2]. Earnings Expectations - 10x Genomics is expected to report a quarterly loss of $0.27 per share, reflecting a year-over-year change of +10% [3]. - Revenue is projected to be $142.39 million, down 6.1% from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised 1.46% higher in the last 30 days, indicating a positive reassessment by analysts [4]. - The Most Accurate Estimate for 10x Genomics is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +11.39% [12]. Earnings Surprise Prediction - A positive Earnings ESP reading suggests a likely earnings beat, especially when combined with a Zacks Rank of 1 [10]. - 10x Genomics currently holds a Zacks Rank of 1, indicating strong potential for beating the consensus EPS estimate [12]. Historical Performance - In the last reported quarter, 10x Genomics was expected to post a loss of $0.35 per share but instead reported earnings of $0.28, resulting in a surprise of +180% [13]. - Over the past four quarters, the company has exceeded consensus EPS estimates three times [14]. Industry Context - In the Zacks Medical Info Systems industry, Nyxoah SA is expected to report a loss of $0.61 per share, indicating a year-over-year change of -10.9% [18]. - Nyxoah's revenue is expected to be $1.95 million, up 40.3% from the previous year [18]. - Despite a higher Most Accurate Estimate leading to an Earnings ESP of +19.67%, Nyxoah's Zacks Rank of 4 (Sell) complicates predictions for an earnings beat [19].

Core Insights - Several small- and mid-cap biotech and medical stocks experienced significant after-hours trading activity on September 26, driven by clinical updates, investor presentations, and strategic announcements. Company Summaries - **Enanta Pharmaceuticals Inc. (ENTA)**: The stock surged 20% in after-hours trading to $9.48 after closing at $7.90, following the announcement of upcoming topline results from its Phase 2b study on zelicapavir for RSV treatment in high-risk adults [2][3]. - **Acumen Pharmaceuticals Inc. (ABOS)**: Shares rebounded 12.67% to $1.60 after closing at $1.42, driven by renewed interest in its Alzheimer's pipeline, particularly the Phase 2 candidate Sabirnetug (ACU193) [4]. - **Delcath Systems Inc. (DCTH)**: The stock gained 6.00% in after-hours trading to $11.39 after closing at $10.74, following renewed investor interest in its CHOPIN Phase 2 trial data presentation scheduled for ESMO 2025 Congress [5][6]. - **Vivos Therapeutics Inc. (VVOS)**: The stock climbed 4.81% to $3.27 after closing at $3.12, likely due to renewed interest following recent positive clinical trial results for its pediatric OSA treatment [7][8]. - **Xilio Therapeutics (XLO)**: Shares rose 4.28% to $0.83 after closing at $0.7959, driven by enthusiasm surrounding the initiation of a Phase 2 trial for its tumor-activated IL-12 candidate, which also triggered a $17.5 million payment from Gilead [9][10]. - **Nyxoah SA (NYXH)**: The stock increased 3.77% to $4.68 after closing at $4.51, supported by optimism regarding its international expansion and a recent patent infringement lawsuit against Inspire Medical Systems [11].

Group 1: Financial Performance - Standard BioTools reported a quarterly loss of $0.04 per share, consistent with the Zacks Consensus Estimate, compared to a loss of $0.08 per share a year ago [1] - The company posted revenues of $41.96 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 5.35%, and up from $37.21 million year-over-year [2] - The current consensus EPS estimate for the upcoming quarter is -$0.04 on revenues of $40.7 million, and for the current fiscal year, it is -$0.14 on revenues of $169.3 million [7] Group 2: Market Performance - Standard BioTools shares have declined approximately 25.4% since the beginning of the year, while the S&P 500 has gained 8.6% [3] - The company has surpassed consensus revenue estimates three times over the last four quarters, but has only exceeded consensus EPS estimates once in the same period [2][1] Group 3: Industry Outlook - The Medical Info Systems industry, to which Standard BioTools belongs, is currently ranked in the top 36% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact investor decisions [5]

Group 1 - Privia Health reported quarterly earnings of $0.02 per share, missing the Zacks Consensus Estimate of $0.05 per share, and down from $0.03 per share a year ago, representing an earnings surprise of -60.00% [1] - The company posted revenues of $521.15 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 11.24%, compared to year-ago revenues of $422.33 million [2] - Privia Health has topped consensus revenue estimates four times over the last four quarters [2] Group 2 - The stock's immediate price movement will depend on management's commentary on the earnings call and future earnings expectations [3] - Privia Health shares have added about 1.2% since the beginning of the year, underperforming the S&P 500's gain of 7.9% [3] Group 3 - The current consensus EPS estimate for the coming quarter is $0.07 on revenues of $474.01 million, and $0.21 on revenues of $1.91 billion for the current fiscal year [7] - The estimate revisions trend for Privia Health was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Group 4 - The Medical Info Systems industry, to which Privia Health belongs, is currently in the top 37% of over 250 Zacks industries, suggesting a favorable outlook [8]

Financial Performance - Outset Medical reported a quarterly loss of $0.84 per share, significantly better than the Zacks Consensus Estimate of a loss of $1.76, and an improvement from a loss of $7.05 per share a year ago, representing an earnings surprise of +52.27% [1] - The company posted revenues of $31.42 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 5.54% and up from $27.39 million in the same quarter last year [2] Stock Performance - Outset Medical shares have declined approximately 15.3% since the beginning of the year, contrasting with the S&P 500's gain of 7.1% [3] - The current Zacks Rank for Outset Medical is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Earnings Outlook - The consensus EPS estimate for the upcoming quarter is -$1.61 on revenues of $30.4 million, and for the current fiscal year, it is -$5.99 on revenues of $121.7 million [7] - The estimate revisions trend for Outset Medical was mixed ahead of the earnings release, which could change following the recent report [6] Industry Context - The Medical Info Systems industry, to which Outset Medical belongs, is currently ranked in the top 30% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]

While Clover Health Investments has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Clover Health Investments, Corp. (CLOV) came out with quarterly ear ...

Core Points - Nyxoah SA announced a conditional issuance of up to 5 million ordinary shares under its existing at-the-market equity offering programs [3] - The total number of ordinary shares that can be sold and issued under the Company's ATM has increased to 5,662,694, which includes 662,694 shares remaining from a previous issuance decision made on December 22, 2022 [3][4] - The shares may be sold at prevailing USD market prices on the Nasdaq Global Market at the time of sale [4]